From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12receptor antagonist with a Ki values of 24.9 nM. The P2Y12receptor plays a crucial role in platelet aggregation. Antithrombotic effect .
Clopidogrel is an orally active platelet inhibitor that targets P2Y12receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
P2Y12 antagonist 1 (compound 26) is a P2Y12receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .
Selatogrel (ACT-246475) is a reversible and selective P2Y12receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy .
Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12receptor antagonist for the treatment of platelet aggregation.
Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12receptor antagonist for the treatment of platelet aggregation[1][2].
R-138727, the thiol-containing active metabolite of Prasugrel, is an irreversible platelet P2Y12receptor inhibitor. R-138727 inhibits ADP-induced platelet aggregation .
AR-C124910XX is a metabolite of Ticagrelor (HY-10064 ). Ticagrelor is a reversible oral P2Y12receptor antagonist, and can be used for study of platelet aggregation .
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12receptor inhibitor that exerts antiplatelet effects .
cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite . Clopidogrel is an orally active platelet inhibitor that targets P2Y12receptor .
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Regrelor disodium (INS 50589) is a platelet P2Y12receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research .
AZD1283 is a potent P2Y12receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .
Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Prasugrel-d4 is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[2].
Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptorP2Y12, and inhibits ADP-induced platelet activation and aggregation .
ADP-β-S trilithium is the trilithium salt form of ADP-β-S (HY-134353). ADP-β-S trilithium is the activator for P2Y12receptor, which upregulates levels of IL-1βand IL-6 production in microglial cells, promotes the phosphorylation and nuclear translocation of NF-κB, and enhances the activation of the NLRP3 inflammasome .
MRS2395, an dipivaloyl derivative, is a potent P2Y12receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .
PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .
MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .
MRS 2211 sodium hydrate is a competitive P2Y13receptor antagonist (pIC50= 5.97). MRS 2211 sodium hydrate is highly selective to the P2Y13receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the P2Y13receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system .
Oral antiplatelet agent 1 is a potent P2Y12receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Yreceptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .
2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent purinergic P2Yreceptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-MeSADP has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-MeSADP induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .
P2RY12 Protein, a receptor for adenosine diphosphate (ADP) and adenosine triphosphate (ATP), inhibits the adenylyl cyclase second messenger system via G-proteins. Unlike uridine diphosphate (UDP) and uridine triphosphate (UTP), P2RY12 crucially regulates platelet aggregation and blood coagulation, serving as a key regulator in these physiological processes. P2RY12 Protein, Human (Cell-Free, His) is the recombinant human-derived P2RY12 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of P2RY12 Protein, Human (Cell-Free, His) is 342 a.a., with molecular weight of 42.2 kDa.
Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12receptor antagonist for the treatment of platelet aggregation[1][2].
Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
Prasugrel-d4 is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation[2].
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12receptor antagonist, and inhibits ADP-induced platelet aggregation .
Inquiry Online
Your information is safe with us. * Required Fields.
